Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS
Liselotte van Bloemendaal, Jennifer S. ten Kulve, Susanne E. la Fleur, et al.
Journal of Endocrinology (2013) Vol. 221, Iss. 1, pp. T1-T16
Open Access | Times Cited: 252

Showing 1-25 of 252 citing articles:

The Discovery and Development of Liraglutide and Semaglutide
Lotte Bjerre Knudsen, Jesper Lau
Frontiers in Endocrinology (2019) Vol. 10
Open Access | Times Cited: 628
Brain Insulin Resistance at the Crossroads of Metabolic and Cognitive Disorders in Humans
Stephanie Kullmann, Martin Heni, Manfred Hallschmid, et al.
Physiological Reviews (2016) Vol. 96, Iss. 4, pp. 1169-1209
Open Access | Times Cited: 481
DPP4 in diabetes
Diana Röhrborn
Frontiers in Immunology (2015) Vol. 6
Open Access | Times Cited: 387
Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial
Juan P. Frías, Cristian Guja, Elise Hardy, et al.
The Lancet Diabetes & Endocrinology (2016) Vol. 4, Iss. 12, pp. 1004-1016
Closed Access | Times Cited: 353
GLP-1 Receptor Activation Modulates Appetite- and Reward-Related Brain Areas in Humans
Liselotte van Bloemendaal, Richard G. IJzerman, Jennifer S. ten Kulve, et al.
Diabetes (2014) Vol. 63, Iss. 12, pp. 4186-4196
Closed Access | Times Cited: 324
GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
Marcel H.A. Muskiet, Lennart Tonneijck, Mark M. Smits, et al.
Nature Reviews Nephrology (2017) Vol. 13, Iss. 10, pp. 605-628
Closed Access | Times Cited: 313
Effects of GLP-1 on appetite and weight
Meera Shah, Adrian Vella
Reviews in Endocrine and Metabolic Disorders (2014) Vol. 15, Iss. 3, pp. 181-187
Open Access | Times Cited: 269
Safety of Semaglutide
Mark M. Smits, Daniël H. van Raalte
Frontiers in Endocrinology (2021) Vol. 12
Open Access | Times Cited: 173
SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management
Michaël J.B. van Baar, Charlotte C. van Ruiten, Marcel H.A. Muskiet, et al.
Diabetes Care (2018) Vol. 41, Iss. 8, pp. 1543-1556
Open Access | Times Cited: 170
Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials
Mihaela-Simona Popoviciu, Lorena Păduraru, Galal Yahya, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 13, pp. 10449-10449
Open Access | Times Cited: 103
Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus
Juan José Gorgojo Martínez, Pedro Mezquita‐Raya, Juana Carretero Gómez, et al.
Journal of Clinical Medicine (2022) Vol. 12, Iss. 1, pp. 145-145
Open Access | Times Cited: 95
The Role of Glp-1 Receptor Agonists in Insulin Resistance with Concomitant Obesity Treatment in Polycystic Ovary Syndrome
Krzysztof Bednarz, Karolina Kowalczyk, Marlena Cwynar, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 8, pp. 4334-4334
Open Access | Times Cited: 76
Neurobiological Mechanisms of Nicotine Reward and Aversion
Lauren Wills, Jessica L. Ables, Kevin M. Braunscheidel, et al.
Pharmacological Reviews (2022) Vol. 74, Iss. 1, pp. 271-310
Open Access | Times Cited: 73
Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review
Manoj K. Mahapatra, Muthukumar Karuppasamy, Biswa Mohan Sahoo
Pharmaceutical Research (2022) Vol. 39, Iss. 6, pp. 1233-1248
Open Access | Times Cited: 69
Obesity in Adolescents
Aaron S. Kelly, Sarah Armstrong, Marc P. Michalsky, et al.
JAMA (2024) Vol. 332, Iss. 9, pp. 738-738
Closed Access | Times Cited: 17
Effects of Glucagon-like Peptide-1 Receptor Agonists on Upper Endoscopy in Diabetic and Non-Diabetic Patients
Danial Nadeem, Mahdi Taye, Matthew Still, et al.
Gastrointestinal Endoscopy (2024) Vol. 100, Iss. 4, pp. 745-749
Open Access | Times Cited: 16
Mechanisms of GLP-1 receptor agonist-induced weight loss: A review of central and peripheral pathways in appetite and energy regulation
Areesha Moiz, Kristian B. Filion, Michael A. Tsoukas, et al.
The American Journal of Medicine (2025)
Open Access | Times Cited: 2
Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease
Paula L. McClean, Christian Hölscher
Neuropharmacology (2014) Vol. 86, pp. 241-258
Closed Access | Times Cited: 147
GLP-1 acts on habenular avoidance circuits to control nicotine intake
Luis M. Tuesta, Zuxin Chen, Alexander Duncan, et al.
Nature Neuroscience (2017) Vol. 20, Iss. 5, pp. 708-716
Open Access | Times Cited: 137
Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program
Johan Jendle, George Grunberger, Thomas Blevins, et al.
Diabetes/Metabolism Research and Reviews (2016) Vol. 32, Iss. 8, pp. 776-790
Open Access | Times Cited: 134
Liraglutide and obesity: a review of the data so far
Ellen E. Ladenheim
Drug Design Development and Therapy (2015), pp. 1867-1867
Open Access | Times Cited: 125
Centrally Acting Agents for Obesity: Past, Present, and Future
Ann A. Coulter, Candida J. Rebello, Frank L. Greenway
Drugs (2018) Vol. 78, Iss. 11, pp. 1113-1132
Open Access | Times Cited: 121
Defined Paraventricular Hypothalamic Populations Exhibit Differential Responses to Food Contingent on Caloric State
Chia Li, Jovana Navarrete, Jing Liang-Guallpa, et al.
Cell Metabolism (2018) Vol. 29, Iss. 3, pp. 681-694.e5
Open Access | Times Cited: 120
Brain reward‐system activation in response to anticipation and consumption of palatable food is altered by glucagon‐like peptide‐1 receptor activation in humans
Liselotte van Bloemendaal, Dick J. Veltman, Jennifer S. ten Kulve, et al.
Diabetes Obesity and Metabolism (2015) Vol. 17, Iss. 9, pp. 878-886
Closed Access | Times Cited: 118
GLP-1 receptor agonist promotes brown remodelling in mouse white adipose tissue through SIRT1
Fen Xu, Beisi Lin, Xiaobin Zheng, et al.
Diabetologia (2016) Vol. 59, Iss. 5, pp. 1059-1069
Open Access | Times Cited: 118
Page 1 - Next Page

Scroll to top